Last reviewed · How we verify
Panzytrat 25.000 FIP-E units of Lipase
Panzytrat 25.000 FIP-E units of Lipase is a Pancreatic enzyme replacement therapy Small molecule drug developed by Foundation for Liver Research. It is currently FDA-approved for Pancreatic insufficiency (chronic pancreatitis, cystic fibrosis, pancreatic surgery), Fat malabsorption disorders. Also known as: Pancreatine of porcine-origin.
Panzytrat is a pancreatic enzyme replacement therapy containing lipase that aids in the digestion and absorption of dietary fats.
Panzytrat is a pancreatic enzyme replacement therapy containing lipase that aids in the digestion and absorption of dietary fats. Used for Pancreatic insufficiency (chronic pancreatitis, cystic fibrosis, pancreatic surgery), Fat malabsorption disorders.
At a glance
| Generic name | Panzytrat 25.000 FIP-E units of Lipase |
|---|---|
| Also known as | Pancreatine of porcine-origin |
| Sponsor | Foundation for Liver Research |
| Drug class | Pancreatic enzyme replacement therapy |
| Target | Triglycerides and dietary lipids |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Lipase is a pancreatic enzyme that breaks down triglycerides and other lipids in the small intestine. In pancreatic insufficiency, endogenous lipase production is reduced, leading to malabsorption of fats and fat-soluble vitamins. Panzytrat supplements this deficiency by providing exogenous lipase to restore normal fat digestion and nutrient absorption.
Approved indications
- Pancreatic insufficiency (chronic pancreatitis, cystic fibrosis, pancreatic surgery)
- Fat malabsorption disorders
Common side effects
- Abdominal discomfort
- Nausea
- Diarrhea
- Constipation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panzytrat 25.000 FIP-E units of Lipase CI brief — competitive landscape report
- Panzytrat 25.000 FIP-E units of Lipase updates RSS · CI watch RSS
- Foundation for Liver Research portfolio CI
Frequently asked questions about Panzytrat 25.000 FIP-E units of Lipase
What is Panzytrat 25.000 FIP-E units of Lipase?
How does Panzytrat 25.000 FIP-E units of Lipase work?
What is Panzytrat 25.000 FIP-E units of Lipase used for?
Who makes Panzytrat 25.000 FIP-E units of Lipase?
Is Panzytrat 25.000 FIP-E units of Lipase also known as anything else?
What drug class is Panzytrat 25.000 FIP-E units of Lipase in?
What development phase is Panzytrat 25.000 FIP-E units of Lipase in?
What are the side effects of Panzytrat 25.000 FIP-E units of Lipase?
What does Panzytrat 25.000 FIP-E units of Lipase target?
Related
- Drug class: All Pancreatic enzyme replacement therapy drugs
- Target: All drugs targeting Triglycerides and dietary lipids
- Manufacturer: Foundation for Liver Research — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Pancreatic insufficiency (chronic pancreatitis, cystic fibrosis, pancreatic surgery)
- Indication: Drugs for Fat malabsorption disorders
- Also known as: Pancreatine of porcine-origin
- Compare: Panzytrat 25.000 FIP-E units of Lipase vs similar drugs
- Pricing: Panzytrat 25.000 FIP-E units of Lipase cost, discount & access